Core Viewpoint - The A-share market shows a slight increase with the Shanghai Composite Index at 3630.45 points, reflecting a gain of 0.36% as of 14:02, with a total trading volume of 14153.35 billion yuan [1] Group 1: Market Performance - The A-share market has a total trading volume of 14153.35 billion yuan [1] - The Shanghai Composite Index is at 3630.45 points, indicating a 0.36% increase [1] Group 2: Stocks with Death Cross - A total of 13 A-shares have experienced a death cross, where the 5-day moving average falls below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Information Development: 5-day MA at 44.98 yuan, 10-day MA at 45.61 yuan, a difference of -1.39% [2] - Zhun Oil Shares: 5-day MA at 7.31 yuan, 10-day MA at 7.41 yuan, a difference of -1.34% [2] - Xin Nuo Wei: 5-day MA at 52.60 yuan, 10-day MA at 53.19 yuan, a difference of -1.11% [2]

近日，迪瑞医疗科技股份有限公司（以下简称"迪瑞医疗"）发布2025年半年度业绩预告显示，期内预计实现归属股东净利润约为-2200万元至-3300万元，上 年同期盈利1.65亿元，预计扣非后净利润约为-2600万元至-3900万元，上年同期盈利1.62亿元，同比由盈转亏。 这家曾被华润看好并通过基金收购控股的国内IVD器械平台，正在面临着利润率下滑、资产减值与政策影响等多重挑战。 华润系唯一国内IVD器械平台，2024年利润骤降 根据介绍，迪瑞医疗成立于1992年，是国内专业从事医疗器械、诊断试剂及配套耗材研发、生产与销售的企业，2014年于A股上市。 2020年，华润系收购迪瑞医疗28%的股权，成为控股股东。迪瑞医疗成为华润系大健康产业上市公司，与华润医药、华润医疗、华润三九、东阿阿胶、华润 双鹤、江中药业共同形成了具备医药工业、医药商业和医疗机构等全产业链的产业集群。 不过，从近几年业绩来看，华润系入股之后，并未影响迪瑞医疗业务出现巨大转变。2021-2024年，公司营收分别为9.09亿元、12.2亿元、13.78亿元和12.18 亿元，对应归母净利润分别为2.1亿元、2.62亿元、2.76亿元和1.42亿 ...

Core Viewpoint - Jiangzhong Pharmaceutical (600750) has shown a mixed performance in its latest financial results, with a decrease in total revenue but an increase in net profit, indicating potential areas for investment consideration [1][2]. Financial Performance - As of the first quarter of 2025, Jiangzhong Pharmaceutical reported total revenue of 1.184 billion yuan, a year-on-year decrease of 7.03% [1]. - The company's net profit attributable to shareholders was 285 million yuan, reflecting a year-on-year increase of 5.91% [1]. - The company's non-recurring net profit was 261 million yuan, which represents a year-on-year decrease of 1.14% [1]. - Key financial ratios include a current ratio of 1.972, a quick ratio of 1.710, and a debt-to-asset ratio of 28.51% [1]. Market Activity - As of July 30, 2025, Jiangzhong Pharmaceutical's stock closed at 22.28 yuan, with an increase of 1.13% [1]. - The trading volume was 115,400 hands, with a total transaction amount of 257 million yuan [1]. - There was a net outflow of main funds amounting to 10.4685 million yuan, accounting for 4.07% of the transaction amount [1]. Company Background - Jiangzhong Pharmaceutical Co., Ltd. was established in 1996 and is located in Nanchang City, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 6,294.44958 million yuan and a paid-in capital of 6,290.17624 million yuan [1]. - The legal representative of the company is Liu Weiquan [1]. Investment and Intellectual Property - Jiangzhong Pharmaceutical has made investments in 19 external enterprises and participated in 5,000 bidding projects [2]. - The company holds 1,189 trademark registrations and 653 patent registrations, along with 152 administrative licenses [2].

Group 1 - The 2025 Zero Carbon Industry (Changping) Green Investment Conference was successfully held in Beijing, focusing on the theme "New Quality Drives Digital Intelligence Integration for Zero Carbon Transformation" with over 200 representatives from government, research institutions, and leading enterprises discussing the development path of the zero-carbon industry [1] - The conference highlighted the achievements in China's energy transition under the "dual carbon" goals, including the continuous expansion of renewable energy and significant improvements in energy efficiency, while also addressing challenges such as energy supply reliability and the pressure for traditional energy to transition to cleaner forms [3] - The China Classification Society Quality Certification Company has completed over 10,000 greenhouse gas verifications and over 1,000 emission reduction project audits since 2008, emphasizing its role in leading the construction of zero-carbon standards [5] Group 2 - The domestic voluntary carbon market has shown significant progress since its launch in January 2024, with a registration of 9.48 million tons of emission reductions and a transaction volume exceeding 200 million yuan, indicating a stable CCER price between 80-90 yuan per ton [7] - The National Climate Strategy Center is accelerating the establishment of a product carbon footprint management system, planning to develop about 200 key product accounting rules and a national carbon footprint factor database by 2027-2030 [9] - The "Zero Carbon China" evaluation information system was launched, featuring a standardized evaluation system, intelligent data analysis, and a visual monitoring platform to support various stakeholders in achieving low-carbon transitions [17][19] Group 3 - The "Zero Carbon China" initiative has entered a new phase of large-scale practice, with 15 exemplary cases selected that demonstrate significant potential for promotion across various scenarios, including zero-carbon parks, factories, and villages [21] - Jiangzhong Pharmaceutical has implemented a systematic approach to green transformation, achieving a 30% share of self-generated green electricity and a 60% reduction in energy consumption through innovative technologies [23] - The National Energy Biomass Power Generation Group has contributed 100 billion kilowatt-hours of green electricity and reduced carbon dioxide emissions by 100 million tons, while promoting a "green thermal power + bio-economy" strategy [25][26]

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Core Viewpoint - The establishment of a 1 billion yuan investment fund by companies under China Resources, in collaboration with Shanghai Fosun Pharmaceutical and Chengdu state-owned enterprises, aims to focus on the pharmaceutical and health sectors, particularly in innovative drug development and strategic emerging industries [2][4]. Group 1: Fund Structure and Partners - The fund, named China Resources Pharmaceutical (Chengdu) Innovation Investment Fund, has a total capital of 100 million yuan, with various partners contributing different amounts [3]. - The general partner (GP) is China Resources Pharmaceutical (Chengdu) Enterprise Management Partnership (Limited Partnership), while limited partners (LPs) include several pharmaceutical companies and investment funds [2][3]. - The fund's lifespan is set for 7 years, with a 3-year investment period and a 4-year exit period, extendable by 1 year upon partner approval [3]. Group 2: Investment Focus - The fund will concentrate on the pharmaceutical health sector and strategic emerging industries, targeting areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices, and traditional Chinese medicine [4]. - The involvement of the Chengdu Bio-City Jingchuang Equity Investment Fund indicates a strong potential for project implementation within the Chengdu Tianfu International Bio-City [4]. Group 3: Historical Context - An earlier fund, the China Resources Pharmaceutical (Shantou) Industry Investment Fund, was established 8 years ago but did not perform as expected, failing to reach its initial target of 2.5 billion yuan [4][6]. - The Shantou fund entered a liquidation phase in December 2024, having not achieved the anticipated scale, which affected the contributions of its partners [5][6].

Core Insights - The article highlights the recent establishment of various funds across multiple regions in China, focusing on sectors such as biotechnology, artificial intelligence, new energy, and advanced manufacturing [1][2][3][6][20]. Fund Establishments - Jiangsu Province has launched a green low-carbon industry fund with a scale of 2 billion yuan, targeting investments in green technologies and smart energy [2]. - Yunnan Province has registered a 5 billion yuan advanced manufacturing equity investment fund, aimed at transforming traditional industries and fostering emerging sectors [3]. - A new 10 billion yuan direct investment fund is being set up in Xiamen to support local SMEs in strategic emerging industries [5]. - Jiangsu's strategic emerging industry mother fund has surpassed 100 billion yuan in total scale, with 41 specialized funds established [6]. - A 10 billion yuan AI-focused fund has been announced in Ma'anshan, emphasizing investments in the AI industry [7]. - Cangzhou is initiating a 1 billion yuan green chemical industry fund to support the development of a high-end, green, and intelligent chemical industry [8][9]. - The national-level sub-fund in Ordos has a scale of 1.6 billion yuan, focusing on advanced manufacturing and information technology [10]. Policy Changes - The Ministry of Finance has introduced new regulations to optimize the long-term assessment mechanism for state-owned commercial insurance companies, shifting the focus to multi-period indicators to enhance the role of insurance funds in supporting the real economy [40][41][42].

AI基金长盛养老健康混合A（000684）披露2025年二季报，第二季度基金利润265.91万元，加权平均基金份额本期利润0.0437元。报告期内，基金净值增长 率为2.1%，截至二季度末，基金规模为1.27亿元。 该基金属于灵活配置型基金，长期投资于医药医疗股票。截至7月18日，单位净值为2.171元。基金经理是郝征，目前管理4只基金近一年均为正收益。其 中，截至7月18日，长盛医疗量化股票A近一年复权单位净值增长率最高，达29.74%；长盛景气优选混合最低，为13.82%。 基金管理人在二季报中表示，2025 年二季度，医药行业仍然是创新药及产业链为主题。同时三生制药的大额BD落地，使得整体创新药的行情继续得以延 续。本产品主要围绕A股医药产业链进行布局。二季度适当做了一定的分散，减持了部分创新药标的，增加部分高值耗材和中药的配置。但是从产业趋势 看，国内创新药及创新药产业链的产业浪潮仍在进行中，因此对于产业链中业绩增速快或者出海预期确定的标的会选择在调整中继续增加配置。 截至7月18日，长盛养老健康混合A近三个月复权单位净值增长率为13.68%，位于同类可比基金116/138；近半年复权单位净值增长率为 ...

Core Insights - The AI Fund, focusing on state-owned enterprise reform, reported a profit of 5.35 million yuan for Q2 2025, with a net asset value growth rate of 3.15% [3] - As of July 17, 2025, the fund's unit net value was 1.121 yuan, and it had a total scale of 170 million yuan [3][17] - The fund manager, Wang Yu, oversees two funds, both of which have shown positive returns over the past year, with the highest growth rate being 9.37% for the state-owned enterprise reform fund [3] Fund Performance - The fund's one-year net value growth rate is 9.37%, ranking 484 out of 601 comparable funds [4] - Over the past three months, the fund's net value growth rate was 3.51%, ranking 552 out of 607 [4] - The fund's three-year net value growth rate is -11.87%, ranking 233 out of 468 [4] Risk Metrics - The fund's three-year Sharpe ratio is -0.0946, ranking 311 out of 468 comparable funds [10] - The maximum drawdown over the past three years is 32.45%, ranking 355 out of 461 [12] - The highest quarterly drawdown occurred in Q1 2020, at 24.98% [12] Investment Strategy - The fund's portfolio is concentrated in stable industries and high-quality companies, with significant overlap in high-dividend sectors such as home appliances, public utilities, light industry, and competitive chemical and machinery sectors [3] - The average stock position over the past three years was 88.1%, with a peak of 94.15% in mid-2024 and a low of 73.51% in Q3 2023 [15] Top Holdings - As of Q2 2025, the fund's top ten holdings include Zijin Mining, Jiangsu Bank, Guodian Nanjing Automation, Yuntianhua, Hangzhou Bank, Jiangzhong Pharmaceutical, Yili Group, Shanjin International, Xiyang Group, and Goldwind Technology [21]

Group 1 - The third China International Supply Chain Promotion Expo (Chain Expo) was held from July 16 to 20 in Beijing, showcasing vibrant cooperation between domestic and foreign enterprises in the health and wellness sector [1] - Starbucks China participated for the third consecutive time, forming a carbon reduction alliance with strategic partners and showcasing its ready-to-drink business for the first time at the expo [2] - L'Oréal, the only foreign beauty company at the expo, highlighted its innovative capabilities in the daily chemical and beauty industry, with 62% of its sales coming from products manufactured in China [2][4] Group 2 - Tsingtao Group presented its complete supply chain system at the expo, celebrating the 50th anniversary of China-Thailand diplomatic relations and emphasizing the importance of China in the global supply chain [3] - The CEO of Tsingtao Group expressed confidence in China's economic prospects and the unique advantages of its supply chain, viewing the expo as a valuable opportunity for international collaboration [3] - Traditional Chinese medicine companies showcased innovative health experiences, with Yiling Pharmaceutical presenting a series of innovative traditional Chinese medicines based on the theory of collateral diseases [4] Group 3 - China Resources Group exhibited its comprehensive health industry ecosystem, focusing on the theme of "Guarding Health Across the Chain, Creating a Better Life" through multimedia interactions and core product displays [5] - Guangdong province, as the guest province, showcased 64 enterprises, including China Resources Group and TCL, highlighting the integration of traditional medicine and modern technology [5] - The health life chain exhibition area demonstrated China's core position in the global health industry chain and the innovative fusion of traditional medicine with modern technology [5]